Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients

Ngo, Katherine, Kotecha, Dipak, Walters, Julia Ae, Manzano, Luis, Palazzuoli, Alberto, van Veldhuisen, Dirk J and Flather, Marcus (2010) Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients. Cochrane Database of Systematic Reviews (1). CD007613. ISSN 1465-1858

Full text not available from this repository. (Request a copy)


Chronic heart failure (CHF) is a leading cause of morbidity and mortality worldwide. Anaemia is a common (12-55%) co-morbid condition and is associated with worsening symptoms and increased mortality. Anaemia is treatable and can be targeted in the treatment of patients with CHF. Erythropoiesis-stimulating agents (ESA), supplemented by iron therapy, are used to treat anaemia in chronic kidney disease and cancer, however safety concerns have been raised in these patients. The clinical benefit and safety of these agents in CHF remains unclear.

Item Type: Article
Uncontrolled Keywords: anemia,heart failure,hematinics,humans,randomized controlled trials as topic,sdg 3 - good health and well-being ,/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
Depositing User: Pure Connector
Date Deposited: 20 Jan 2014 16:12
Last Modified: 24 Oct 2022 05:36
DOI: 10.1002/14651858.CD007613.pub2

Actions (login required)

View Item View Item